ESMO Congress 2026

The protagonist this time is intismeran, the personalized mRNA therapeutic cancer vaccine from Moderna and Merck, used with Keytruda in melanoma. On class background, one point must be stated first: none of the six attached background references touches on cancer vaccines, melanoma, or mRNA therapeutics, and the material contains no published Phase 3 trial of a comparable asset for comparison; that evidence is undisclosed and to be confirmed in this material, so irrelevant references will not be forced in. What actually frames this readout is market expectation: per the live posts, MRNA had already rallied 587% year-to-date to $254.48, with optimism fully priced in.

The meeting news went public early because the embargo was lifted following a breach: detailed data from the Phase 3 melanoma trial confirmed that intismeran plus Keytruda met key endpoints, with the personalized mRNA therapy reducing disease recurrence by 42% compared to standard treatment; STAT reporters subsequently added much more information and context (reporting originally saved for Saturday). At the same time, the live posts carry a second, equally important thread, a "sell the news" market reaction: on the day of the leak MRNA plunged 17.57% to $202.63, down as much as 24% intraday, on 50.4M shares versus a 19.1M daily average, attributed to DMFS (distant metastasis-free survival) falling short of whisper numbers; the put/call ratio spiked to 1.85 with 154K puts traded, institutional flow was 88% bearish, aggressively hitting the $200 and $175 strikes, with $176.00 seen as the institutional support zone.

Relative to prior understanding, the step forward is that the asset's conclusion moves from "met key endpoints" to confirmation at the level of detailed data, with the 42% reduction in recurrence risk as the core number; it also puts the gap between statistical success and market pricing on the table — primary endpoints met yet DMFS below expectations — which explains why a positive readout came with a sharp selloff. It should be noted that the same batch of live posts also covers ENERGIZE (negative Phase 3 in bladder cancer), RAMIRIS (GEA), EV-SG-zim (first-line metastatic urothelial cancer), and a Phase 2 mKRAS PDAC peptide vaccine, among other readouts; these belong to different pipelines and are not the main line of this piece.

The limitations are equally clear: the live posts did not disclose the Phase 3 trial's sample size, follow-up duration, or the specific DMFS values or hazard ratio — all undisclosed; the data were released early via a leak, so the formal report should be the final word; and a single day's stock and options flow only reflects immediate trading sentiment, which neither changes the clinical conclusion nor constitutes any investment judgment.